No current treatments for primary brain tumors achieve significant direct bloodstream access to the brain. Cleveland Clinic’s involved in a broad range of trials aiming to change that.
Results from the first 12 patients treated using this novel CED device show high volumes of chemotherapy delivered to enhancing and nonenhancing regions of recurrent high-grade gliomas.
Approval of the Cleveland Multiport Catheter, designed for higher-volume drug distribution to glioma tumors, clears a path for its use in IND-based clinical trials of new drugs and biologics.
This novel CED device promises larger volume of drug distribution than with prior CED devices. Early human testing in glioma patients supports that hope, and use in other CNS conditions is being explored.